Another newly FDA-approved cream for the treatment of plaque psoriasis is roflumilast 0.3%, a selective, topical, highly potent phosphodiesterase (PDE)-4 inhibitor, that was also found to be efficacious and safe in the treatment of plaque psoriasis. The gene discussed is PDE4A; the disease is psoriasis vulgaris.